{"nct_id":"NCT04220866","title":"Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)","status":"COMPLETED","status_verified_date":"2023-10","start_date":"2020-03-04","start_date_type":"ACTUAL","primary_completion_date":"2022-09-30","primary_completion_date_type":"ACTUAL","completion_date":"2022-09-30","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MRK"]}